🍽 Resveratrol Sirtuin Activation Evidence Simulator

The First Wave — Resveratrol as a Direct Sirtuin Activator

Early reports suggested resveratrol directly boosted SIRT1 activity.

• 2003: Reported year (Placeholder citation marker)
• Cell-free: Assay type (Fluorogenic substrate)
• ~13x: Claimed fold-activation (Placeholder figure)
• High: Initial excitement (Placeholder note)

Original activation claim

Placeholder: cell-free fluorogenic assay reported large SIRT1 activation.

Rapid scientific and media interest

Placeholder: findings drew broad attention across longevity research.

The Fluorophore Problem — Questioning the Original Assay

Follow-up work found the assay dye itself was driving the signal.

• Dye-linked peptide: Artifact source (Placeholder detail)
• Much weaker: Native substrate result (Placeholder figure)
• 2005: Key rebuttal year (Placeholder citation marker)
• Controversy: Field reaction (Placeholder note)

Dye-dependent signal discovered

Placeholder: activation seen only with fluorophore-conjugated substrate.

Native peptide re-testing

Placeholder: unlabeled substrate assays showed minimal direct activation.

Getting There — The Oral Bioavailability Problem

Resveratrol is metabolized rapidly, limiting active plasma exposure.

• <1%: Oral bioavailability (Placeholder figure)
• Glucuronidation: Main metabolism route (Placeholder detail)
• Short: Plasma half-life (Placeholder note)
• High: Dose needed (animal) (Placeholder figure)

Rapid first-pass metabolism

Placeholder: gut and liver conjugation clears resveratrol quickly.

Implications for dosing

Placeholder: high oral doses required to reach effective tissue levels.

Inconsistent Outcomes Across Later Trials

Subsequent animal and human studies produced inconsistent effects.

• Some: Positive animal studies (Placeholder figure)
• Mixed: Human trial outcomes (Placeholder note)
• Small/variable: Effect size (Placeholder detail)
• Inconclusive: Meta-analyses (Placeholder note)

Variable trial designs

Placeholder: differing doses and endpoints hindered comparison.

Reassessing the sirtuin hypothesis

Placeholder: doubts grew about direct allosteric SIRT1 activation.

Next-Generation Sirtuin-Activating Compounds

Newer STAC molecules were engineered for potency and delivery.

• STACs: New compound class (Placeholder detail)
• ~1000x: Potency improvement (Placeholder figure)
• Improved: Bioavailability fix (Placeholder note)
• Ongoing trials: Clinical status (Placeholder note)

Rational compound redesign

Placeholder: structure-based design improved activator specificity.

Where the field stands now

Placeholder: cautious optimism replaces early overstated claims.

Placeholder: lessons from resveratrol reshaped sirtuin drug development.